Biosimilars

Biosimilars | Overview & Forecast | G7 | 2017

In 2016, branded biologic sales in oncology, immunology, endocrinology, and nephrology across the major markets exceeded $70 billion. Sales from biosimilars in the same therapy areas and regions …

Biosimilars | Current Treatment | US/EU | 2017

There have been significant economic benefits in Europe since the approval of the first biosimilar more than a decade ago. Although the first FDA biosimilar approval was in 2015, biosimilars are…